多西他赛周疗法治疗老年人晚期非小细胞肺癌的疗效观察

Curative effect of weekly dose doctaxale for the treatment of elderly patients with advanced non-small cell lung cancer

目的 观察多西他赛单药每周方案治疗老年人晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应.方法 50例经病理学或细胞学确诊的老年晚期NSCLC患者（≥60岁）,治疗组（28例）应用多西他赛35 mg/m^2,静脉滴注1 h,第1、8、15天,28 d为1个周期;对照组（22例）给予最佳支持治疗（BSC）.结果 治疗组有效率（RR）32.0%明显高于对照组的10.0%（Х^2=8.156,P＜0.01）;治疗组中位肿瘤进展时间（TTP）、中位生存期（OS）、1年生存率（6.0个月、12.5个月、40.1%）明显高于对照组（2.5个月、5.2个月、9.7%）（Х^2=7.234、7.812、8.989,均P＜0.01）;治疗组治疗后KPS评分（89.5±10.2）分高于对照组治疗后的（76.0±9.9）分（t=2.330,P＜0.05）;治疗组治疗后咳嗽、咯血、LCSS评分[（92.4±16.9）分、（93.4±17.5）分]明显高于对照组治疗后[（82.4±15.0）分、（81.3±16.0）分]（t=2.2150、2.245,均P＜0.05）.结论 多西他赛周疗法治疗老年人NSCLC有较好的疗效,并能有效改善症状,且患者耐受性较好.

Objective To investigate the clinical efficacy and toxicity of patients with advanced non-small cell lung cancer（NSCLC） treated with weekly dose doctaxale. Methods 50 elderly cases with histologically or cytologically diagnosed advanced NSCLC were treated in treatment group（n=28） ,using docetaxel（at a dose of 35mg/m^2 infused on day 1 and 8,21 days as one cycle）. Control group （n=22） , using best supportive care （BSC）. Results The response rate 32. 0% in treatment group were significantly higher than 10. 0% in control group（Х^2=8. 156, P〈0.01） ;The median time to tumor progression （TTP） , median survival（OS） ,1-year survival rate（6. 0month,12. 5 month,40. 1%） in treatment group were significantly higher（2. 5month,5. 2 month, 10. 3%） than those in control group（Х^2=7.234,7. 812,8.989,all P〈0.01） ;The KPS score（89.5 ±10.2）points after treatment were higher than the control group after treatment （76. 0 ± 9. 9） points which was significantly different （t =2. 330, P〈0. 05）; The score of LCSS in cough,hemoptysis,chest pain,shortness of breath[（92.4 ±16.9） points, （93.4 ±17.5） points]after treatment,were significantly higher than the control group[（82. 4 ± 15. 0） points, （81. 3 ± 16. 0） points] which were significantly different（t = 2. 2150,2.245, all P〈0. 05）. Conclusion The weekly dose doctaxale was a feasible , well-tolerated, and active scheme in the treatment of elderly patients with advanced NSCLC.